Citations

Clear

363 citation(s) found for "Gray, RJ".

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Cohen, Joshua G. , Miller, David S. , Robertson, Sharon E. , Hendrickson, Andrea Wahner, Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Konecny, Gottfried E. , Moroney, John W. , Ratner, Elena , Schorge, John O., Werner, Theresa L. , Chen, Lee-may, DeRosa, Marie, Eisenhauer, Eric , Leiserowitz, Gary S. , Litkouhi, Babak , McHale, Michael , Percac‐Lima, Sanja , Rodabaugh, Kerry J. , Vargas, Roberto , Jones, Frankie, Kovách, E, Hang, Lisa E., Ramakrishnan, Swathi , Armstrong, Deborah K. , Miller, David S , Liu, Joyce F. , Berchuck, Andrew , Backes, Floor , Grisham, Rachel Nicole , Leath, Charles A , Martin, Lainie P. , Matei, Daniela , Barroilhet, Lisa , Uppal, Shitanshu , Gershenson, David M. , Thaker, Premal H. , Zsíros, Emese , Behbakht, Kian , Kovach, Emily, Alvarez, Ronald D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 512-519

10.6004/jnccn.2024.0052 | PMID 39413835 Get It

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
87: It’s Hot! A Unique ECMO Strategy for Severe Drug Induced Hyperthermia-Related Acute Respiratory Distress Syndrome (ARDS)
Boakye-Wenzel, Heather, McNickle, Allison G. , Kuruvilla, Kevin, Modi, Kush, Dugan, Mark, Gray, Johnny, Pinholster, Kyle, Schears, Gregory, Dalton, Heidi , Kioka, Mutsumi John , Pinholster, Kyle

Mayo Clinic

ASAIO Journal | September 28, 2024 | Volume: 70 | Issue: Supplement 4 | Pages: 39-39

10.1097/01.mat.0001069992.18167.5e Get It

Neuropsychology practice guidance for the neuropsychiatric aspects of Long COVID
Considine, Ciaran , Becker, Jacqueline , Hoskinson, Kristen R. , Ng, Rowena , Vargas, Gray, Puente, Antonio Enrique, Lippa, Sara M. , Whiteside, Douglas M. , Koterba, Christine H , Becker, Jacqueline H , Ng, Rowena , Basso, Michael R. , Whiteside, Douglas , Puente, Antonio E.

Mayo Clinic

The Clinical Neuropsychologist | August 23, 2024 | Volume: 39 | Issue: 4 | Pages: 870-898

10.1080/13854046.2024.2392943 | PMID 39177216 Get It

Quality measure for screening for adult obstructive sleep apnea by primary care providers: 2024 update after measure maintenance
Lloyd, Robin M. , Crawford, T’Auna, Donald, Ryan, Gray, Diedra D., Junna, Mithri R. , Lewin, Daniel , Revana, Amee , Schutte-Rodin, Sharon, Healy, William J.

Mayo Clinic

Journal of Clinical Sleep Medicine | July 29, 2024 | Volume: 20 | Issue: 11 | Pages: 1819-1822

10.5664/jcsm.11294 | PMID 39069961 Get It

NODDI in gray matter is a sensitive marker of aging and early AD changes
Yu, Xi , Przybelski, Scott A. , Lesnick, Timothy G. , Raghavan, Sheelakumari , Graff‐Radford, Jonathan , Lowe, Val J. , Kantarci, Kejal, Knopman, David S., Petersen, Ronald C. , Jack, Clifford R. , Kantarci, Kejal , Jack, Clifford R , Kantarci, Kejal , Reid, Robert I. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 29, 2024 | Volume: 16 | Issue: 3 | Pages: No page available

10.1002/dad2.12627 | PMID 39077685 Get It

AbstractINTRODUCTIONAge‐related and Alzheimer's disease (AD) dementia–related neurodegeneration impact brain health. While morphometric measures from T1‐weighted scans are established biomarkers, they may be less sensitive to earlier changes. Neurite orientation dispersion and density imaging (NODDI), offering biologically meaningful interpretation of tissue microstructure, may be an advanced brain health biomarker.METHODSWe contrasted regional gray matter NODDI and morphometric evaluations concerning their correlation with (1) age, (2) clinical diagnosis stage, and (3) tau pathology as assessed by AV1451 positron emission tomography.RESULTSOur study hypothesizes that NODDI measures are more sensitive to aging and early AD changes than morphometric measures. One NODDI output, free water fraction (FWF), showed higher sensitivity to age‐related changes, generally better effect sizes in separating mild cognitively impaired from cognitively unimpaired participants, and stronger associations with regional tau deposition than morphometric measures.DISCUSSIONThese findings underscore NODDI's utility in capturing early neurodegenerative changes and enhancing our understanding of aging and AD.Highlights Neurite orientation dispersion and density imaging can serve as an effective brain health biomarker for aging and early Alzheimer's disease (AD). Free water fraction has higher sensitivity to normal brain aging. Free water fraction has stronger associations with early AD and regional tau deposition.
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
Lampert, Rachel , Day, Sharlene M. , Ainsworth, Barbara E. , Burg, Matthew M. , Marino, Bradley S. , Salberg, Lisa , Tome, Maite , Abrams, Dominic J. , Aziz, Peter F. , Barth, Cheryl , Behr, Elijah R. , Bell, Cheyanne , Berul, Charles I. , Bos, J. Martijn , Cannom, David S. , Cannon, Bryan C. , Concannon, Maryann, Czosek, Richard J. , Dubin, Anne M. , Dziura, James , Erickson, Christopher C. , Etheridge, Susan P. , Gray, Belinda , Haglund-Turnquist, Carla , Johnsrude, Christopher L. , Lara, Alice, Saarel, Elizabeth V. , Sanatani, Shubhayan , Shah, Maully J. , Simone, Laura, Tomaselli, Gordon F., Ware, James S. , Zaręba, Wojciech , Ackerman, Michael J. , Day, Sharlene , Burg, Matthew , Tome Esteban, Maria Teresa , Bos, Johan M , Cannon, Bryan C , Cerrone, Marina , Czosek, Richard J , Dubin, Anne M , Dziura, James , Erickson, Christopher C , Estes, N.A. Mark , Etheridge, Susan P , Goldenberg, Ilan , Gray, Belinda , Haglund-Turnquist, Carla M , Harmon, Kimberly G , James, Cynthia A , Johnsrude, Christopher , Kannankeril, Prince J , Law, Ian H , Link, Mark S. , Molossi, Silvana M , Olshansky, Brian , Noseworthy, Peter A , Saarel, Elizabeth V , Sanatani, Shubhayan , Shah, Maully , Skinner, Jonathan R , Ware, James S , Webster, Gregory , Zareba, Wojciech , Zipes, Douglas P , Ackerman, Michael J , Behr, Elijah Raphael , Abrams, Dominic J , Bradley, David J. , Cerrone, Marina , Goldenberg, Ilan , Harmon, Kimberly G. , James, Cynthia A. , Kannankeril, Prince J. , Law, Ian H. , Li, Fangyong , Olshansky, Brian , Noseworthy, Peter A. , Skinner, Jonathan R. , Webster, Gregory , Zipes, Douglas P.

Mayo Clinic

Circulation | July 25, 2024 | Volume: 150 | Issue: 7 | Pages: 516-530

10.1161/circulationaha.123.067590 | PMID 39051104 Get It

BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.
Operational readiness playbook: A go-to approach to control chaos
Nelson, Suzanne, Barclay, Jason E., Gray, Richard, Jasperson, Jan C., Reinschmidt, Karen J. , Nelson, Suzanne, Gray, Richard J.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 3 | Issue: 4 | Pages: 329

10.69554/mhrq5233 Get It

As project leaders plan large, transformational initiatives, impacted departmental leaders are often forgotten. Operational leaders are in need of a practical, concise guide to prepare for project activities and allocate resources. The Plummer Project change management team of Mayo Clinic created a single source of timelines and tasks with links to more detailed information, termed a ‘playbook’ for operational leaders. The tool was dynamic and provided the operations-relevant project timeline, required preparedness activities and essential references. This paper analyses the format and content of this playbook to assist other organisations with the execution of complex projects. The playbook provided clarity, efficiency and cohesiveness with deep benefits to the project team and organisation.
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
Matteson, Kelsey, Ardeshir, Fatemeh, Gray, Jhanelle E. , Espinar, Javier Baena , Grohé, Christian , Pancirer, Danny, Cheung, Justin Matthew, Watson, Alexander, Kaldas, David , Kim, Chul , Awosika, Nichola, Chiang, Anne C. , Nassar, Amin H. , Kwiatkowski, David J. , Nana, Frank Aboubakar , Citarella, Fabrizio , Sridhar, Arthi , Crowley, Fionnuala , Sankar, K. Nathan , Naqash, Abdul Rafeh

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8106-8106

10.1200/jco.2024.42.16_suppl.8106 Get It

8106 Background: Due to lack of prospective data, the optimal first line treatment approach for patients (pts) with pure LCNEC histology remains uncertain. Methods: Across 17 centers, we conducted a retrospective analysis of metastatic pure LCNEC (diagnosed at local institutions) who received 1st-line systemic therapy between 2015-2023. Pts were either treated with chemotherapy (chemo), immunotherapy (IO), or a combination (chemoIO). Clinical outcomes were progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and treatment-related adverse events (trAE) as defined using CTCAE 5.0. Survival analysis by genomic alteration status ( TP53, RB1, STK11, KEAP1, KRAS) and PD-L1 status were performed. Results: We identified 161 pts with median age of 67 years (IQR: 58-83) at 1st line systemic therapy; 54% (n = 87) were males. Median follow-up was 55 months (mo), 62 mo, and 29 mo for the chemo, IO, and chemoIO groups, respectively. 79% (n = 127) were former or current smokers. 1st-line treatments were chemo (n = 94), IO (n = 11), or chemoIO (n = 56). Of 85 pts with PD-L1 status, 58 (68%) were 0% and 27 (32%) were ≥1%. The most common chemo regimen was platinum-etoposide (n = 72, 78%). ChemoIO regimens included carboplatin/etoposide/atezolizumab (n = 23, 43%) and carboplatin/pemetrexed/pembrolizumab (n = 17, 31%). In the IO group, 1 patient received dual IO. Lung (n = 74, 46%) and liver (n = 71, 41%) were the most common sites of metastasisThere was no significant difference in PFS across the groups (median PFS [mPFS] chemoIO: 5.7 mo, 95% CI: 5.0-6.3, chemo: 5.1 mo, 95% CI: 3.1-5.9; IO: 3.6 mo, 95% CI: 1.7-6.5) on multivariable analysis adjusting for ECOG and “M” stage (p = 0.2 and 0.24 for chemoIO-chemo and chemoIO-IO comparisons, respectively). There was no difference in OS (mOS chemo: 11 mo, 95% CI: 7.6-17.4; IO: 13.6 mo, 95% CI: 5.9-not reached; chemoIO: 12.2 mo, 95% CI: 7.4-20.6, p = 0.5 and 0.8 for chemoIO-chemo and chemoIO-IO comparisons, respectively). ORR was 35.2% (31/88) in chemo, 25% (2/8) in IO, and 35.7% (20/56) in chemoIO ( p= 0.46). There were no significant differences in PFS and OS outcomes by treatment group when divided by genetic profile (n = 79, methods), or by PD-L1 status (0% vs ≥1%). Any grade trAE occurred in 48 (51%), 5 (45%), and 28 (50%) pts treated with chemo, IO, and chemoIO, respectively. Grade ≥3 toxicity profiles are shown (table). Conclusions: For 1st-line treatment of LCNEC, similar PFS, OS, and ORR were seen for chemo, IO, and chemoIO. This questions the added benefit of chemoIO compared to chemo alone, and warrants future clinical trials to discern the optimal 1st line treatment. [Table: see text]
Molecular Breast Imaging Biopsy with a Dual-Detector System
Hunt, Katie N. , Conners, Amy Lynn , Gray, Lacey R., Hruska, Carrie B. , O’Connor, Michael K. , Gray, Lacey, Hruska, Carrie B , O'Connor, Michael K

Mayo Clinic

Radiology: Imaging Cancer | June 7, 2024 | Volume: 6 | Issue: 4 | Pages: No page available

10.1148/rycan.230186 | PMID 38847615 Get It